Compare ELS & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELS | NBIX |
|---|---|---|
| Founded | 1992 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 13.2B |
| IPO Year | 1994 | 1996 |
| Metric | ELS | NBIX |
|---|---|---|
| Price | $63.87 | $128.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 22 |
| Target Price | $70.85 | ★ $180.36 |
| AVG Volume (30 Days) | ★ 1.2M | 906.6K |
| Earning Date | 04-20-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | 2.55 | ★ 41.95 |
| EPS | 2.01 | ★ 4.67 |
| Revenue | ★ $1,531,382,000.00 | $161,626,000.00 |
| Revenue This Year | $3.97 | $22.85 |
| Revenue Next Year | $4.69 | $10.36 |
| P/E Ratio | $31.87 | ★ $28.21 |
| Revenue Growth | 0.34 | ★ 977.51 |
| 52 Week Low | $57.63 | $92.32 |
| 52 Week High | $69.00 | $160.18 |
| Indicator | ELS | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 45.23 |
| Support Level | $58.56 | $124.09 |
| Resistance Level | $68.73 | $136.74 |
| Average True Range (ATR) | 1.00 | 4.22 |
| MACD | 0.10 | 0.16 |
| Stochastic Oscillator | 66.45 | 40.54 |
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 455 properties across the US with a higher concentration in the Sunbelt; 38% of the company's properties are in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations. More than 70% of the company's properties are either age-restricted or have an average resident age over 55.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.